Overview

The Metformin Active Surveillance Trial (MAST) Study

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.
Phase:
Phase 3
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Metformin